Literature DB >> 3629550

Evidence for a saturable mechanism of disappearance of standard heparin in rabbits.

B Boneu, C Caranobe, A M Gabaig, D Dupouy, P Sie, M R Buchanan, J Hirsh.   

Abstract

This work demonstrates that after bolus intravenous injection standard heparin (SH) disappearance results from the combination of a saturable and a non saturable mechanism. Pharmacokinetics and pharmacodynamics of SH were studied by measuring the disappearance of increasing doses (5 - 500 anti-factor Xa U/kg) of 125I-heparin and of its biological effects. CPM curves allowed to determine the half lives of heparin according to the dose injected. The half lives were clearly dose dependent and reached a plateau over 100 anti-factor Xa U/kg. The complex curve which describes the amount of heparin cleared per time unit after any given dose has been resolved into its two components reflecting a saturable and a non saturable mechanism of disappearance. For the doses less than 100 anti-factor Xa U/kg the saturable mechanism was preeminent and the anti-factor Xa activity disappearance followed an exponential pattern; for the doses less than 100 anti-factor Xa U/kg the contribution of the non saturable mechanism becomes more important and the anti-factor Xa activity disappearance followed a concave-convex pattern. Further experiments showed that the heparin half life shortened as the circulating anti-factor Xa activity decreased; this phenomenon may explain the concave-convex pattern of the curve of the anticoagulant effect observed after injection of large doses of SH.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3629550     DOI: 10.1016/0049-3848(87)90075-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Heavy Heparin: A Stable Isotope-Enriched, Chemoenzymatically-Synthesized, Poly-Component Drug.

Authors:  Brady F Cress; Ujjwal Bhaskar; Deepika Vaidyanathan; Asher Williams; Chao Cai; Xinyue Liu; Li Fu; Vandhana M-Chari; Fuming Zhang; Shaker A Mousa; Jonathan S Dordick; Mattheos A G Koffas; Robert J Linhardt
Journal:  Angew Chem Int Ed Engl       Date:  2019-04-01       Impact factor: 15.336

2.  Hepatic uptake of a modified low molecular weight heparin in rats.

Authors:  G Stehle; E A Friedrich; H Sinn; A Wunder; J Harenberg; C E Dempfle; W Maier-Borst; D L Heene
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 3.  Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors:  L B Barradell; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 4.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 5.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 6.  Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?

Authors:  Kristian B Johansen; Torben Balchen
Journal:  Exp Hematol Oncol       Date:  2013-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.